Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Calcifediol→

Calcifediol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
19356-17-3
Molecular formula
C27H44O2
Molecular weight
400.6 g/mol
Drug class
25-hydroxyvitamin D3vitamin D prohormone and precursor of calcitriol
Mechanism of action
Calcifediol (25-hydroxyvitamin D3) is converted in the kidney and other tissues to 1,25-dihydroxyvitamin D (calcitriol), which activates the vitamin D receptor and regulates calcium, phosphate and parathyroid hormone homeostasis.
Indications / reported uses
  • Treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency using the extended-release formulation; immediate-release products may have different vitamin D deficiency indications

Sources: US DailyMed — RAYALDEE (extended-release calcifediol) · NLM MeSH — Calcifediol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Calcifediol Environmental Risk Assessment (ERA) (the Calcifediol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.